Cargando…
Two RSV Platforms for G, F, or G+F Proteins VLPs
Respiratory syncytial virus (RSV) causes substantial lower respiratory tract disease in children and at-risk adults. Though there are no effective anti-viral drugs for acute disease or licensed vaccines for RSV, palivizumab prophylaxis is available for some high risk infants. To support anti-viral a...
Autores principales: | Ha, Binh, Yang, Jie E., Chen, Xuemin, Jadhao, Samadhan J., Wright, Elizabeth R., Anderson, Larry J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551478/ https://www.ncbi.nlm.nih.gov/pubmed/32824936 http://dx.doi.org/10.3390/v12090906 |
Ejemplares similares
-
Detection of RSV Antibodies in Human Plasma by Enzyme Immunoassays
por: Jadhao, Samadhan J., et al.
Publicado: (2016) -
The importance of RSV F protein conformation in VLPs in stimulation of neutralizing antibody titers in mice previously infected with RSV
por: Cullen, Lori M., et al.
Publicado: (2017) -
Functional Features of the Respiratory Syncytial Virus G Protein
por: Anderson, Larry J., et al.
Publicado: (2021) -
An RSV Live-Attenuated Vaccine Candidate Lacking G Protein Mucin Domains Is Attenuated, Immunogenic, and Effective in Preventing RSV in BALB/c Mice
por: Roe, Molly K, et al.
Publicado: (2022) -
RSV pre-fusion F protein enhances the G protein antibody and anti-infectious responses
por: Su, Caixia, et al.
Publicado: (2022)